Article

U.S. Officials Brace for Huge Task of Operating Health Exchanges

health insurance

Obama administration officials are getting ready to set up and operate new markets in about half the states, where local officials appear unwilling or unable to do so.

President Obama

h

ealth care law

The markets, known as exchanges, are a centerpiece of ’s , and running them will be a herculean task that federal officials never expected to perform.

Read the full story: http://tinyurl.com/c9h2ftt

Source: The New York Times

Related Videos
CK Wang, MD, COTA
Pieter Sonneveld, MD, PhD
Naim Alkhouri, MD
Antoine Keller, MD
Pieter Sonneveld, MD, PhD
Dr K. Vish Viswanath
Ajai Chari, MD
Naim Alkhouri, MD
Andrew Chapman, DO
Related Content
The findings also show that ropeginterferon alfa-2b is an effective therapy for molecular response in early polycythemia vera. | Image credit: fotogurmespb.- stock.adobe.com
May 23rd 2025

Molecular Response to Therapy Linked With Event-Free Survival in PV

Jared Kaltwasser
New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

Jared Kaltwasser
Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.
managed care cast logo
November 27th 2024

Operationalizing Bispecifics in Multiple Myeloma

Mary Caffrey Laura Joszt, MA
Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.
Adolescent patients were more likely to be most bothered by feelings of anxiety or atopic dermatitis affecting their daily activities. | Image Credit: InfiniteStudio - stock.adobe.com
May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor
The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.
In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo